Protembis, a frontrunner in medical innovation based in Germany, has secured a significant financial boost.
The European Investment Bank (EIB) has invested €20 million to advance Protembis’ development of a cerebral embolic protection device.
Transcatheter aortic valve replacement (TAVR) is widely accepted as a breakthrough in cardiac treatment. However, the procedure is not without its risks. Dislodged debris from the aortic arch can enter three major arteries leading to the brain. This debris poses a severe risk of stroke and cognitive decline, by blocking smaller cerebral vessels.
Protembis has tackled this predicament with their ProtEmbo device, designed to act as a shield within the aortic arch. Implemented during TAVR, the device serves to prevent harmful particles from reaching the brain, potentially transforming cardiac care.
This endeavour also underscores the EIB’s commitment to aiding European companies in contributing positively to public health. By fostering such advancements, the bank enables significant strides in medical technology.
ProtEmbo’s goal is to dramatically reduce neurological complications in TAVR patients.
While still undergoing clinical evaluation, the device’s prospects are promising. The outcome of these trials will be pivotal in proving its efficacy and safety.
A successful innovation could mean a paradigm shift in managing cardiac procedures, offering safer solutions and improved patient care.
The combined efforts not only stimulate economic growth but also advance healthcare services, ultimately benefiting numerous patients worldwide.
Protembis is embarking on a pivotal FDA-approved study, with hopes to validate ProtEmbo against traditional methods.
The €20 million EIB funding will expedite these trials, aiming to showcase ProtEmbo as a superior cerebral protection method.
These developments are being closely monitored by stakeholders in the healthcare sector, anticipating a breakthrough in patient safety protocols.
The EIB and Protembis partnership reflects a broader trend in Europe prioritising healthcare innovations.
European investments in medical technologies are increasing, highlighting the continent’s role in developing breakthroughs that benefit global health.
Support from entities like the EIB not only advances technology but also reinforces Europe’s position as a leader in healthcare solutions.
The backing from EIB is set to propel Protembis’ innovations, with expectations of significant strides in cerebral protection methods during heart surgery.
If successful, this initiative will mark a pivotal point in cardiac care, promising safer and more effective medical procedures.
In collaboration with the EIB, Protembis is set to spearhead advancements in medical technology.
The ProtEmbo device could significantly impact cardiac procedures, improving safety and patient outcomes.
